FTC Chair Lina Khan (Photo by Michael Brochstein/Sipa USA)(Sipa via AP Images)
November 7, 2023 12:47 PM ESTUpdated 02:47 PM
FDA+
Law

FTC chal­lenges more than 100 drug patents owned by Ab­b­Vie, As­traZeneca, Boehringer and sev­en oth­ers

Zachary Brennan

Senior Editor

The Fed­er­al Trade Com­mis­sion on Tues­day chal­lenged more than 100 patents as im­prop­er­ly or in­ac­cu­rate­ly list­ed in the FDA’s Or­ange Book of gener­ic drugs. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times